NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
- Conditions
- Adult Acute Promyelocytic Leukemia (M3)Blastic Phase Chronic Myelogenous LeukemiaChildhood Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in Transformation
- Interventions
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00006213
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Obesity and Fatty Acid Flux Comparison Trials
- Conditions
- Obesity
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 30
- Registration Number
- NCT00074945
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model
- Conditions
- HypercholesterolemiaHypertensionDepressionDiabetes Mellitus, Type 2
- First Posted Date
- 2003-12-19
- Last Posted Date
- 2010-01-13
- Target Recruit Count
- 79
- Registration Number
- NCT00074633
- Locations
- 🇺🇸
Nutrition Department, University of California, Davis, Davis, California, United States
🇺🇸Western Human Nutrition Research Center, Davis, California, United States
Kidney Transplantation in Patients With Cystinosis
- Conditions
- Cystinosis
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 11
- Registration Number
- NCT00074516
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
- Conditions
- LymphomaLeukemiaMyelodysplastic SyndromeMyeloproliferative DisordersMultiple Myleoma
- Interventions
- Procedure: Peripheral blood stem cell (PBSC) transplantationGenetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cellsProcedure: Allogeneic hematopoietic stem cell transplant (HSCT)Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 442
- Registration Number
- NCT00074490
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-12-12
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00021983
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00074243
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00004242
- Locations
- 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
- Conditions
- Recurrent Non-small Cell Lung CancerRecurrent Prostate CancerStage III Prostate CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerStage IV Prostate CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00074022
- Locations
- 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00074321
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States